AKBA vs AMGN vs IQV vs CRL vs MEDP

For growth investors, Akebia Therapeutics, Inc.

(AKBA) is the stronger pick with 47. 5% revenue growth year-over-year, versus -0. 9% for Charles River Laboratories International, Inc. (CRL). IQVIA Holdings Inc. (IQV) offers the better valuation at 22. 8x trailing P/E (14. 1x forward), making it the more compelling value choice. Analysts rate Akebia Therapeutics, Inc. (AKBA) a "Buy" — based on 11 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

On trailing P/E, IQVIA Holdings Inc.

(IQV) is the cheapest at 22. 8x versus Medpace Holdings, Inc. at 28. 1x. On forward P/E, IQVIA Holdings Inc. is actually cheaper at 14. 1x. The PEG ratio (P/E divided by earnings growth rate) is the most growth-adjusted single valuation metric: IQVIA Holdings Inc. wins at 0. 35x versus Amgen Inc. 's 5. 04x — a PEG below 1. 0 traditionally signals the market is underpricing earnings growth.

Over the past 5 years, Medpace Holdings, Inc.

(MEDP) delivered a total return of +159. 4%, compared to -62. 2% for Akebia Therapeutics, Inc. (AKBA). Over 10 years, the gap is even starker: MEDP returned +1426% versus AKBA's -86. 0%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

By beta (market sensitivity over 5 years), Amgen Inc.

(AMGN) is the lower-risk stock at 0. 61β versus Charles River Laboratories International, Inc. 's 1. 44β — meaning CRL is approximately 135% more volatile than AMGN relative to the S&P 500. On balance sheet safety, Medpace Holdings, Inc. (MEDP) carries a lower debt/equity ratio of 55% versus 7% for Akebia Therapeutics, Inc. — giving it more financial flexibility in a downturn.

By revenue growth (latest reported year), Akebia Therapeutics, Inc.

(AKBA) is pulling ahead at 47. 5% versus -0. 9% for Charles River Laboratories International, Inc. (CRL). On earnings-per-share growth, the picture is similar: Akebia Therapeutics, Inc. grew EPS 93. 7% year-over-year, compared to -1555. 0% for Charles River Laboratories International, Inc.. Over a 3-year CAGR, MEDP leads at 20. 1% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

Amgen Inc.

(AMGN) is the more profitable company, earning 21. 0% net margin versus -3. 6% for Charles River Laboratories International, Inc. — meaning it keeps 21. 0% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: AMGN leads at 29. 1% versus 9. 9% for AKBA. At the gross margin level — before operating expenses — AKBA leads at 83. 3%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

The PEG ratio (forward P/E divided by expected earnings growth rate) is the most precise measure of undervaluation relative to growth potential.

By this metric, IQVIA Holdings Inc. (IQV) is the more undervalued stock at a PEG of 0. 35x versus Amgen Inc. 's 5. 04x. A PEG below 1. 0 is traditionally considered the threshold for growth-adjusted undervaluation. On forward earnings alone, IQVIA Holdings Inc. (IQV) trades at 14. 1x forward P/E versus 25. 0x for Medpace Holdings, Inc. — 10. 9x cheaper on a one-year earnings basis. Analyst consensus price targets imply the most upside for AKBA: 239. 0% to $4. 00.

In this comparison, AMGN (2.

9% yield) pays a dividend. AKBA, IQV, CRL, MEDP do not pay a meaningful dividend and should not be held primarily for income.

For long-horizon retirement investors, Amgen Inc.

(AMGN) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0. 61), 2. 9% yield, +158. 1% 10Y return). Both have compounded well over 10 years (AMGN: +158. 1%, CRL: +114. 0%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.

In terms of investment character: AKBA is a small-cap high-growth stock; AMGN is a mid-cap quality compounder stock; IQV is a mid-cap quality compounder stock; CRL is a small-cap quality compounder stock; MEDP is a mid-cap high-growth stock. AMGN pays a dividend while AKBA, IQV, CRL, MEDP do not, making them suitable for different income and tax situations. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.